Wuhan Hiteck Biological Pharma Co.,Ltd

XSEC:300683 Stock Report

Market Cap: CN¥3.7b

Wuhan Hiteck Biological PharmaLtd Valuation

Is 300683 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300683 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 300683's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 300683's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300683?

Key metric: As 300683 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 300683. This is calculated by dividing 300683's market cap by their current revenue.
What is 300683's PS Ratio?
PS Ratio6.1x
SalesCN¥614.85m
Market CapCN¥3.73b

Price to Sales Ratio vs Peers

How does 300683's PS Ratio compare to its peers?

The above table shows the PS ratio for 300683 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.2x
300653 Yantai Zhenghai Biotechnology
10.2x14.7%CN¥3.9b
688136 Kexing Biopharm
2.5x27.9%CN¥3.3b
300238 Guanhao BiotechLtd
9.5xn/aCN¥3.5b
603739 Qingdao Vland Biotech
2.7x8.6%CN¥3.4b
300683 Wuhan Hiteck Biological PharmaLtd
6.1xn/aCN¥3.7b

Price-To-Sales vs Peers: 300683 is good value based on its Price-To-Sales Ratio (6.1x) compared to the peer average (6.2x).


Price to Sales Ratio vs Industry

How does 300683's PS Ratio compare vs other companies in the CN Biotechs Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
603716 Thalys Medical Technology Group
0.9xn/aUS$242.05m
No more companies available in this PS range
300683 6.1xIndustry Avg. 7.4xNo. of Companies9PS048121620+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 300683 is good value based on its Price-To-Sales Ratio (6.1x) compared to the CN Biotechs industry average (7.4x).


Price to Sales Ratio vs Fair Ratio

What is 300683's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300683 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 300683's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies